Doubt is being cast increasingly on the validity of oesophageal pressure measurements in sick infants. Indeed, even in the absence of lung disease extreme prematurity itself can sometimes render such measurements inaccurate. Without accurate and reproducible measurements of oesophageal pressure, dynamic compliance cannot be reliably measured in these groups of infants.
Phototherapy for neonatal hyperbilirubinaemia
Sir, Drs Modi and Keay' conclude that phototherapy without measurement of irradiance is incomplete and inefficient. They would presumably like to see all neonatal units equipped with a radiometer. At a cost of £300 each and assuming one radiometer per 2000 births, this would cost the country approximately £100 000. They have treated well, term babies who had no haemolysis but do not address the question of whether such babies need phototherapy, or indeed any therapy at all.-Haven't the horse and the cart exchanged positions somewhere along the line? Unnecessary efficiency is inefficient efficiency and it has yet to be shown that babies with physiological jaundice benefit from being removed from their mothers and placed under a light with their eyes covered. A reasonable inference from our finding that phototherapy is used badly in well babies is that it is also used badly when its effectiveness is critical-in sick, preterm babies and in rhesus haemolytic disease.
We are also among those who believe that phototherapy is frequently used unnecessarily. While the question of treatment in well, term babies is debated, however, we feel any treatment considered necessary should be effective. We do not suggLst that every neonatal unit in the country be equipped with a radiometer; we do, however, suggest that units providing intensive care are. We further suggest that manufacturers of phototherapy units provide irradiance specifications and that paediatricians appreciate that better use may be made of existing units.
Fibrin stabilising factor in Schonlein-Henoch syndrome Sir, We read with interest the article by Dalens et all which supports our own data.2 In a similar study we showed that some patients have low activity of fibrin stabilising factor in the acute phase of Schonlein-Henoch purpura. Determination of the fibrin stabilising factor in the early stage of Schonlein-Henoch purpura seems to be useful in the prognosis and management of patients, especially those with nephritis. The authors have stated in the summary that an increase in fibrin stabilising factor is associated with recovery. We believe, however, that this is not true in patients with Schonlein-Henoch purpura nephritis. Our results suggest that it is possible for the nephritis to progress after fibrin stabilising factor values return to normal and because of this, patients with a low fibrin stabilising factor value in the acute phase of disease deserve close follow up even if they show a later increase.
